Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

India Proposes Big Push To Pharma Manufacturing And Research; Talks On With Multinational Companies For Vaccine Development Center

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - The Indian government is moving swiftly on a series of new initiatives that seek to position India as a country of choice for big pharmaceutical companies looking to establish research centers and build manufacturing facilities. An outlay of $1 to $2 billion will be made every year through 2020 for the comprehensive action plan, if implemented

Table

View full table

Related Content

Scrip
Pink Sheet
Scrip
Tags:
Latest Headlines

Sanofi To Pursue Smart M&A Pacts And Stick With Early-Stage Oncology R&D

Xaira Launches With $1bn-Plus And End-To-End AI Strategy

Biogen Sees Improving Momentum In Slow Leqembi Launch

Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative

See All
UsernamePublicRestriction

Register

SC072431

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By